{
    "nctId": "NCT05444647",
    "briefTitle": "Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study",
    "officialTitle": "Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female, presenting for the first time with operable breast cancer, who had not received any previous treatment for an invasive malignancy.\n2. Primary tumor greater than (\\>) 2 cm in diameter.\n3. Age \u2265 18 years and \\< 70 years.\n4. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\\</=) 1.\n5. Baseline left ventricular ejection fraction (LVEF) greater than or equal to (\\>/=) 55%\n6. Availability of tumor tissue specimen after surgery.\n7. Histologically proven diagnosis of breast cancer.\n8. Patients have HER2-positive disease. HER2-positive disease was defined as follows: disease which overexpresses HER-2 by immunohistochemistry (IHC) 3+ and/or has HER2 amplification according to fluorescence in situ hybridization (FISH).\n9. Had hormonal receptors (ER and PgR) assessed.\n10. Signed informed consent.\n11. Able to comply with the protocol.\n\nExclusion Criteria:\n\n1. prior ipsilateral breast surgery, ipsilateral radiotherapy, hormonal therapy or systemic chemotherapy\n2. Prolonged antibiotic treatment \\> 10 days within 1 month of neoadjuvant chemotherapy as prevention or suppression of an ongoing infection\n3. Uncontrolled inflammatory bowel disease\n4. pregnant",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}